Jesus Trujillo Vazquez

Jesus Trujillo Vazquez

Auto-generated profile, based on publicly available information

Jesus Trujillo Vazquez

Instituto Universitario de Bio-Orgánica “Antonio González”, Departamento de Química Orgánica, Universidad de La Laguna, 38206 La Laguna, Tenerife, Spain

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2003 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JBJoaquín Barberá
Joaquín Barberá
ECEmma Cavero
Emma Cavero
MLMatthias Lehmann
Matthias Lehmann
JSJosé-Luis Serrano
José-Luis Serrano
TSTeresa Sierra
Teresa Sierra
JVJesús T. Vázquez
Jesús T. Vázquez

13 March 1998 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JBJ. Barberá
J. Barberá
RIR. Iglesias
R. Iglesias
JSJ. L. Serrano
J. L. Serrano
TST. Sierra
T. Sierra
MFM. R. de la Fuente
M. R. de la Fuente
JVJ. T. Vázquez
J. T. Vázquez

6 January 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TMTeresa Mairal
Teresa Mairal
JNJoan Nieto
Joan Nieto
MPMarta Pinto
Marta Pinto
MAMaria Almeida
Maria Almeida
LGLuis Gales
Luis Gales
GVGregorio Valencia
Gregorio Valencia
The thyroid hormone and retinol transporter protein known as transthyretin (TTR) is in the origin of one of the 20 or so known amyloid diseases. TTR self assembles as a homotetramer leaving a central hydrophobic channel with two symmetrical binding sites. The aggregation pathway of TTR into amiloid fibrils is not yet well characterized but in vitro binding of thyroid hormones and other small organic molecules to TTR binding channel results in tetramer stabilization which prevents amyloid formation in an extent which is proportional to the binding constant. Up to now, TTR aggregation inhibitors have been designed looking at various structural features of this binding channel others than its ability to host iodine atoms. In the present work, greatly improved inhibitors have been designed and tested by taking into account that thyroid hormones are unique in human biochemistry owing to the presence of multiple iodine atoms in their molecules which are probed to interact with specific halogen binding domains sitting at the TTR binding channel. The new TTR fibrillogenesis inhibitors are based on the diflunisal core structure because diflunisal is a registered salicylate drug with NSAID activity now undergoing clinical trials for TTR amyloid diseases. Biochemical and biophysical evidence confirms that iodine atoms can be an important design feature in the search for candidate drugs for TTR related amyloidosis.

1 September 1995 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JBJose Barluenga
Jose Barluenga
FAFernando Aznar
Fernando Aznar
AMAlfredo Martin
Alfredo Martin
JVJesus T. Vazquez
Jesus T. Vazquez

1 September 1987 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
WWWilliam T. Wiesler
William T. Wiesler
JVJesus T. Vazquez
Jesus T. Vazquez
KNKoji Nakanishi
Koji Nakanishi

13 May 2003 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
ARAlfredo Roën
Alfredo Roën
JPJuan I. Padrón
Juan I. Padrón
JVJesús T. Vázquez
Jesús T. Vázquez